Cipher Pharmaceuticals Inc. (CPHRF)
- Previous Close
6.81 - Open
6.70 - Bid --
- Ask --
- Day's Range
6.43 - 6.70 - 52 Week Range
2.50 - 7.45 - Volume
5,835 - Avg. Volume
20,072 - Market Cap (intraday)
155.409M - Beta (5Y Monthly) --
- PE Ratio (TTM)
8.04 - EPS (TTM)
0.80 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.
www.cipherpharma.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CPHRF
Performance Overview: CPHRF
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CPHRF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CPHRF
Valuation Measures
Market Cap
155.41M
Enterprise Value
115.94M
Trailing P/E
8.04
Forward P/E
11.78
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.72
Price/Book (mrq)
1.93
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
102.43%
Return on Assets (ttm)
8.12%
Return on Equity (ttm)
29.70%
Revenue (ttm)
22.14M
Net Income Avi to Common (ttm)
22.68M
Diluted EPS (ttm)
0.80
Balance Sheet and Cash Flow
Total Cash (mrq)
41.98M
Total Debt/Equity (mrq)
0.38%
Levered Free Cash Flow (ttm)
2.9M
Research Analysis: CPHRF
Company Insights: CPHRF
CPHRF does not have Company Insights